Results 1 to 10 of about 389 (122)

Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin. [PDF]

Res Pract Thromb Haemost, 2022
Abstract Background Postthrombotic syndrome (PTS) is a long‐term complication after deep vein thrombosis (DVT) and can affect quality of life (QoL). Pathogenesis is not fully understood but inadequate anticoagulant therapy with vitamin K antagonists is a known risk factor for the development of PTS.
Bistervels IM, Bavalia R, Beyer-Westendorf J, Ten Cate-Hoek AJ, Schellong SM, Kovacs MJ, Falvo N, Meijer K, Stephan D, Boersma WG, Ten Wolde M, Couturaud F, Verhamme P, Brisot D, Kahn SR, Ghanima W, Montaclair K, Hugman A, Carroll P, Pernod G, Sanchez O, Ferrari E, Roy PM, Sevestre-Pietri MA, Birocchi S, Wik HS, Hutten BA, Coppens M, Naue C, Grosso MA, Shi M, Lin Y, Quéré I, Middeldorp S, Hokusai PTS Investigators.   +34 more
europepmc   +2 more sources

Number needed to treat for net clinical benefit of oral anticoagulants in Asian patients with atrial fibrillation. [PDF]

J Arrhythm
The number needed to treat for the net benefit (NNTnet) was calculated from the benefit of stroke prevention and risk of major bleeding of warfarin and non‐vitamin K antagonist oral anticoagulants (NOACs) and no oral anticoagulant (OAC). Warfarin had a negative NNTnet compared to no OAC. Only warfarin with TTR 65% has positive NNTnet.
Krittayaphong R, Pumprueg S, Yindeengam A, Lip GYH.   +3 more
europepmc   +2 more sources

Estudios genéticos del metabolismo de la warfarina y su utilidad en la toma de decisiones

Revista Colombiana De Cardiologia, 2022
Introducción: Al momento de valorar la necesidad de realizar un reemplazo quirúrgico valvular cardiaco es posible elegir entre una válvula mecánica o una bioprotésica; la elección debe tener presentes los riesgos de la terapia anticoagulante y la ...
Clara Saldarriaga
exaly   +3 more sources

Desensibilización a warfarina. Reporte de caso

Revista Alergia México, 2021
Antecedentes: La warfarina es un anticoagulante oral ampliamente utilizado en la prevención y tratamiento de patologías tromboembólicas, a la cual se le atribuyen múltiples efectos adversos; no obstante, las descripciones de reacciones de ...
Fernando Steven Fuentes-Abreu, Juan Camilo Ardila-Herrera, María Raigosa   +2 more
doaj   +1 more source

Meta-análisis: Eficacia y seguridad de apixabán frente a warfarina en pacientes con fibrilación auricular para profilaxis de eventos cardiovasculares adversos

Cedamaz, 2022
Los pacientes con fibrilación auricular (FA) requieren terapia anticoagulante para prevenir eventos cardiovasculares adversos. Un fármaco muy empleado es warfarina con beneficios variables e inconsistentes y mayor riesgo de hemorragia.
Mariela Alexandra Idrovo Vallejo, Paula Blandin-Lituma   +1 more
doaj   +1 more source

CYP2C8*3 and *4 define CYP2C8 phenotype: An approach with the substrate cinitapride

Clinical and Translational Science, Volume 15, Issue 11, Page 2613-2624, November 2022., 2022
Abstract Cinitapride is a gastrointestinal prokinetic drug, prescribed for the treatment of functional dyspepsia, and as an adjuvant therapy for gastroesophageal reflux disease. In this study, we aimed to explore the impact of relevant variants in CYP3A4 and CYP2C8 and other pharmacogenes, along with demographic characteristics, on cinitapride ...
Diana María Campodónico, Pablo Zubiaur, Paula Soria‐Chacartegui, Ana Casajús, Gonzalo Villapalos‐García, Marcos Navares‐Gómez, Antía Gómez‐Fernández, Raúl Parra‐Garcés, Gina Mejía‐Abril, Manuel Román, Samuel Martín‐Vílchez, Dolores Ochoa, Francisco Abad‐Santos   +12 more
wiley   +1 more source

Atrial fibrillation bleeding risk and prediction while treated with direct oral anticoagulants in warfarin‐naïve or warfarin‐experienced patients

Clinical Cardiology, Volume 45, Issue 9, Page 960-969, September 2022., 2022
Abstract Background In patients with atrial fibrillation (AF) treated with direct oral anticoagulants (DOAC), bleeding risk scores provide only modest discrimination for major or intracranial bleeding. However, warfarin experience may impact HAS‐BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile ...
Alexander C. Perino, Jun Fan, Krishna Pundi, Susan Schmitt, Mitra Kothari, Natasha Din, Paul A. Heidenreich, Mintu P. Turakhia   +7 more
wiley   +1 more source

Warfarina: fatores que influenciam no índice de normatização internacional

Revista Eletrônica de Enfermagem, 2017
O tratamento com Warfarina reduz a capacidade de coagulação do sangue, sendo acompanhado laboratorialmente pelo tempo de protrombina expresso como no índice de normatização internacional(INR).
Ticiane C. G. F. Campanili, Andrea Cotait Ayoub   +1 more
doaj   +1 more source

3D In Vitro Human Organ Mimicry Devices for Drug Discovery, Development, and Assessment

Advances in Polymer Technology, Volume 2020, Issue 1, 2020., 2020
The past few decades have shown significant advancement as complex in vitro humanized systems have substituted animal trials and 2D in vitro studies. 3D humanized platforms mimic the organs of interest with their stimulations (physical, electrical, chemical, and mechanical).
Aida Rodriguez-Garcia, Jacqueline Oliva-Ramirez, Claudia Bautista-Flores, Samira Hosseini, Mona Semsarilar   +4 more
wiley   +1 more source

Factores genéticos y ambientales asociados con la respuesta a warfarina en pacientes colombianos

Biomédica: revista del Instituto Nacional de Salud, 2010
Introducción. La warfarina es un anticoagulante de difícil manejo por su estrecho margen terapéutico y los numerosos factores que influyen en la respuesta. Objetivo.
Carlos Isaza, Leonardo Beltrán, Julieta Henao, Gloria Porras, Alfredo Pinzón, Álvaro Vallejos, Jorge Machado   +6 more
doaj   +1 more source